These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 27605637)

  • 1. Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007-18.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kaura S
    Health Aff (Millwood); 2016 Sep; 35(9):1588-94. PubMed ID: 27605637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
    Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Projecting future drug expenditures--2012.
    Hoffman JM; Li E; Doloresco F; Matusiak L; Hunkler RJ; Shah ND; Vermeulen LC; Schumock GT
    Am J Health Syst Pharm; 2012 Mar; 69(5):405-21. PubMed ID: 22345420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C; Rusch LM
    J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
    [No Abstract]   [Full Text] [Related]  

  • 6. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O; Zhou Y
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-national comparison of orphan drug policies: implications for the U.S. Orphan Drug Act.
    Thamer M; Brennan N; Semansky R
    J Health Polit Policy Law; 1998 Apr; 23(2):265-90. PubMed ID: 9565894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projecting future drug expenditures--2010.
    Hoffman JM; Doloresco F; Vermeulen LC; Shah ND; Matusiak L; Hunkler RJ; Schumock GT
    Am J Health Syst Pharm; 2010 Jun; 67(11):919-28. PubMed ID: 20484216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National trends in prescription drug expenditures and projections for 2016.
    Schumock GT; Li EC; Suda KJ; Wiest MD; Stubbings J; Matusiak LM; Hunkler RJ; Vermeulen LC
    Am J Health Syst Pharm; 2016 Jul; 73(14):1058-75. PubMed ID: 27170624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
    Tambuyzer E
    Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending.
    Michaeli T; Michaeli DT
    Value Health; 2024 Apr; 27(4):449-457. PubMed ID: 38244983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projecting future drug expenditures--2009.
    Hoffman JM; Shah ND; Vermeulen LC; Doloresco F; Martin PK; Blake S; Matusiak L; Hunkler RJ; Schumock GT
    Am J Health Syst Pharm; 2009 Feb; 66(3):237-57. PubMed ID: 19179637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.
    Sarpatwari A; Beall RF; Abdurrob A; He M; Kesselheim AS
    Health Aff (Millwood); 2018 May; 37(5):732-737. PubMed ID: 29733729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do investors value the FDA orphan drug designation?
    Miller KL
    Orphanet J Rare Dis; 2017 Jun; 12(1):114. PubMed ID: 28629392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.
    Chua KP; Kimmel LE; Conti RM
    Health Aff (Millwood); 2021 Mar; 40(3):453-460. PubMed ID: 33646878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.
    Kesselheim AS; Treasure CL; Joffe S
    PLoS Med; 2017 Jan; 14(1):e1002190. PubMed ID: 28045970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
    Danzon PM
    Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.